Detailed Analysis of Urinary Tract Infections After Robot-Assisted Radical Cystectomy.

Journal: Journal of endourology
PMID:

Abstract

To describe urinary tract infections (UTIs) after robot-assisted radical cystectomy (RARC) and investigate the variables associated with it. A retrospective review of 616 patients who underwent RARC between 2005 and 2019 was performed. Patients were divided into those who developed UTI and those who did not. Patients who developed UTI were further subdivided into three subgroups according to the onset, number, and severity. The Kaplan-Meier method was used to depict time to UTI. Multivariate analysis was used to investigate variables associated with UTI. Two hundred forty (39%) patients were diagnosed with UTI after RARC; 48% occurred within 30 days, 17% within 30-90 days, and 35% at 90 days after RARC. Twenty-three percent of the patients presented with urosepsis. The median (interquartile ratio) time to develop UTI was 1 (0.3-7) month. On multivariate analysis, patients who received neobladders (odds ratio [OR] 2.80; 95% confidence interval [CI] 1.50-5.20;  < 0.01), prolonged hospital stay (OR 1.06; 95% CI 1.03-1.08;  < 0.01), adjuvant chemotherapy (OR 2.20; 95% CI 1.40-3.60;  < 0.01), poor renal function postoperatively (OR 2.30; 95% CI 1.30-3.80;  < 0.01), postoperative hydronephrosis (OR 2.50; 95% CI 1.40-4.50;  < 0.01), ureteroileal anastomotic stricture (OR 2.90; 95% CI 1.50-5.70;  < 0.01), and stented ureteroileal anastomosis (OR 9.35; 95% CI 1.23-71.19;  = 0.03) were associated with UTI after RARC. UTI is common after RARC mainly within the first month after RARC. was the most common causative organism.

Authors

  • Naif A Aldhaam
    Roswell Park Comprehensive Cancer Center, NY, USA.
  • Ahmed A Hussein
    Department of Urology, Applied Technology Laboratory for Advanced Surgery (ATLAS) Program at Roswell Park Cancer Institute, Buffalo, NY; Department of Urology, Cairo University, Cairo, Egypt.
  • Ahmed S Elsayed
    1 A.T.L.A.S (Applied Technology Laboratory for Advanced Surgery) Program, Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Zhe Jing
    1 A.T.L.A.S (Applied Technology Laboratory for Advanced Surgery) Program, Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Jennifer Osei
    Urology Department and Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Zachary Kurbiel
    Urology Department and Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Tarik Babar
    Roswell Park Comprehensive Cancer Center, NY, USA.
  • Sara Khan
    Urology Department and Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Avneet Nagra
    Urology Department and Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Brahm Segal
    Internal Medicine Department, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Qiang Li
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Khurshid A Guru